Medtronic MDT Other Operating Segments, Including Diabetes — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medtronic in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medtronic’s 10-K, filed June 18, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medtronic's other operating segments, including diabetes — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medtronic's other operating segments, including diabetes — net sales?
- Medtronic (MDT) reported other operating segments, including diabetes — net sales of $811.75M in Q1 2026.
- How has Medtronic's other operating segments, including diabetes — net sales changed year-over-year?
- Medtronic's other operating segments, including diabetes — net sales increased by 12.3% year-over-year, from $723M to $811.75M.
- What is the long-term trend for Medtronic's other operating segments, including diabetes — net sales?
- Over 2 years (2024 to 2026), Medtronic's other operating segments, including diabetes — net sales has grown at a 9.5% compound annual growth rate (CAGR), from $2.71B to $3.25B.
- What does other operating segments, including diabetes — net sales mean?
- Total revenue generated by the company's secondary business units, including the diabetes division.
- How do you interpret other operating segments, including diabetes — net sales?
- An increase indicates successful market penetration or product adoption in secondary therapeutic areas, while a decrease may signal competitive pressure or product lifecycle maturity.
- How does other operating segments, including diabetes — net sales compare across companies?
- Peers in the medical device sector typically report revenue by therapeutic area, with diabetes-related segments often evaluated based on innovation cycles and continuous glucose monitoring adoption rates.